SCHEMBL1162260

SCHEMBL1162260

Cc1ccccc1O[C@](C(=O)O)(c1ccccc1C)[C@@H](O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
CYP1A2 P05177 1/20 0.38
ALDH1A1 P00352 3/20 0.36
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
NOTUM Q6P988 1/20 0.35
HTT P42858 2/20 0.35
CASP1 P29466 1/20 0.34
TDP1 Q9NUW8 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GAA P10253 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PPARG P37231 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4668126 1.00 KDM4E (0.38) KDM4ECYP1A2ALDH1A1RXRARXRB
SCHEMBL555425 1.00 KDM4E (0.38) KDM4ECYP1A2ALDH1A1RXRARXRB
SCHEMBL4214182 0.78 HPGD (0.38) KDM4EALDH1A1TDP1SMN1; SMN2GAA
SCHEMBL8188892 0.77 NOTUM (0.36) CYP1A2NOTUMTDP1SMN1; SMN2PPARG
Water SCHEMBL8734708 0.76 NOTUM (0.35) CYP1A2NOTUMTDP1SMN1; SMN2PPARG
SCHEMBL5310850 0.73 ATM (0.38) KDM4ECYP1A2ALDH1A1RXRARXRB
SCHEMBL697581 0.72 CPT2 (0.35) KDM4ECYP1A2ALDH1A1TDP1GAA
SCHEMBL12817104 0.72 CPT2 (0.35) KDM4ECYP1A2ALDH1A1TDP1GAA
Water SCHEMBL28155256 0.71 CPT2 (0.34) KDM4ECYP1A2ALDH1A1TDP1GAA
SCHEMBL31070064 0.71 EDNRB (0.37) SMN1; SMN2GAAL3MBTL1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007075630-A1 METHOD FOR PRODUCING 3-AMINOPIPERIDINE DIASTEREOMER DOW GLOBAL TECHNOLOGIES INC. (US) 2007-07-05 WO claimed
EP-1024137-B1 RESOLUTION OF AMINES ESTEVE LABOR DR (ES) 2003-09-24 EP claimed
US-6187930-B1 REACTING SELECTED AMINE WITH OPTICALLY ACTIVE ACID SELECTED FROM (+)-DITOLUYL-L-TARTARIC ACID AND/OR (-)-DITOLUYL-L-TARTARIC ACID IN SOLVENT TO FORM DIASTEROISOMERIC SALT, SEPARATING, ISOLATING ENANTIOMER LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2001-02-13 US claimed
EP-1024137-A1 RESOLUTION OF AMINES LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2000-08-02 EP claimed
US-11897843-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine REUTER CHEMISCHE APPARATEBAU KG 2024-02-13 US disclosed
EP-4289819-A2 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE Reuter Chemische Apparatebau e.K. (DE) 2023-12-13 EP disclosed
EP-3653607-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPBAU E K (DE) 2023-10-18 EP disclosed
US-20230008387-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPARATEBAU KG (DE) 2023-01-12 US disclosed
US-11472770-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine REUTER CHEMISCHE APPARATEBAU KG 2022-10-18 US disclosed
EP-3653607-A2 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE Reuter Chemische Apparatenbau e.K. (DE) 2020-05-20 EP disclosed
US-20200087257-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPARATEBAU KG (DE) 2020-03-19 US disclosed
US-10464898-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine REUTER CHEMISCHE APPARATEBAU KG (DE) 2019-11-05 US disclosed
US-20050096318-A1 Pharmaceutically active morpholinol GLAXOSMITHKLINE SPA (IT) 2005-05-05 US disclosed
US-6855820-B2 Pharmaceutically active morpholinol SMITHKLINE BEECHAM CORPORATION (US) 2005-02-15 US disclosed
EP-1024137-B1 RESOLUTION OF AMINES ESTEVE LABOR DR (ES) 2003-09-24 EP disclosed
US-20030027827-A1 Pharmaceutically active morpholinol SMITHKLINE BEECHAM CORPORATION 2003-02-06 US disclosed
US-6187930-B1 REACTING SELECTED AMINE WITH OPTICALLY ACTIVE ACID SELECTED FROM (+)-DITOLUYL-L-TARTARIC ACID AND/OR (-)-DITOLUYL-L-TARTARIC ACID IN SOLVENT TO FORM DIASTEROISOMERIC SALT, SEPARATING, ISOLATING ENANTIOMER LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2001-02-13 US disclosed
US-6187930-B1 REACTING SELECTED AMINE WITH OPTICALLY ACTIVE ACID SELECTED FROM (+)-DITOLUYL-L-TARTARIC ACID AND/OR (-)-DITOLUYL-L-TARTARIC ACID IN SOLVENT TO FORM DIASTEROISOMERIC SALT, SEPARATING, ISOLATING ENANTIOMER LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2001-02-13 US disclosed
EP-1024137-A1 RESOLUTION OF AMINES LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2000-08-02 EP disclosed
EP-1024137-A1 RESOLUTION OF AMINES LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2000-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008387-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE NPEPPS, AASDHPPT, DNPEP KDM4E 1366/4885CYP1A2 181/4885ALDH1A1 1655/4885
US-11472770-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine NPEPPS, AASDHPPT, DNPEP KDM4E 1366/4885CYP1A2 181/4885ALDH1A1 1655/4885
US-11897843-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine NPEPPS, AASDHPPT, DNPEP KDM4E 1379/4885CYP1A2 178/4885ALDH1A1 1707/4885
US-20050096318-A1 Pharmaceutically active morpholinol ACHE, COMT, SNCA KDM4E 490/4885CYP1A2 988/4885ALDH1A1 1559/4885
US-20200087257-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE NPEPPS, AASDHPPT, DNPEP KDM4E 1366/4885CYP1A2 181/4885ALDH1A1 1655/4885
US-20030027827-A1 Pharmaceutically active morpholinol ACHE, COMT, MGLL KDM4E 532/4885CYP1A2 919/4885ALDH1A1 1734/4885
US-10464898-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine NPEPPS, AASDHPPT, DNPEP KDM4E 1395/4885CYP1A2 207/4885ALDH1A1 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.